- Home
- NXTC vs SISI Comparison
NXTC vs SISI Comparison
Compare NXTC & SISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- SISI
- Stock Information
- Founded
- NXTC 2015
- SISI 1997
- Country
- NXTC United States
- SISI China
- Employees
- NXTC N/A
- SISI N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- SISI Medicinal Chemicals and Botanical Products
- Sector
- NXTC Health Care
- SISI Health Care
- Exchange
- NXTC Nasdaq
- SISI Nasdaq
- Market Cap
- NXTC 13.9M
- SISI 14.9M
- IPO Year
- NXTC 2019
- SISI 2016
- Fundamental
- Price
- NXTC $0.48
- SISI $0.21
- Analyst Decision
- NXTC Strong Buy
- SISI
- Analyst Count
- NXTC 2
- SISI 0
- Target Price
- NXTC $3.50
- SISI N/A
- AVG Volume (30 Days)
- NXTC 336.1K
- SISI 5.5M
- Earning Date
- NXTC 07-31-2025
- SISI 05-15-2025
- Dividend Yield
- NXTC N/A
- SISI N/A
- EPS Growth
- NXTC N/A
- SISI N/A
- EPS
- NXTC N/A
- SISI N/A
- Revenue
- NXTC N/A
- SISI $9,601,324.00
- Revenue This Year
- NXTC N/A
- SISI N/A
- Revenue Next Year
- NXTC N/A
- SISI N/A
- P/E Ratio
- NXTC N/A
- SISI N/A
- Revenue Growth
- NXTC N/A
- SISI 1133.26
- 52 Week Low
- NXTC $0.22
- SISI $0.18
- 52 Week High
- NXTC $1.82
- SISI $117.65
- Technical
- Relative Strength Index (RSI)
- NXTC 44.82
- SISI 29.00
- Support Level
- NXTC $0.45
- SISI $0.18
- Resistance Level
- NXTC $0.51
- SISI $0.34
- Average True Range (ATR)
- NXTC 0.07
- SISI 0.05
- MACD
- NXTC -0.01
- SISI -0.01
- Stochastic Oscillator
- NXTC 3.24
- SISI 11.25
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.